CSIMarket
 



Abbvie inc   (ABBV)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 


Abbvie inc Segments

 
HUMIRA
   64.66 % of total Revenue
Kaletra
   2.98 % of total Revenue
AndroGel
   3.14 % of total Revenue
Lupron
   3.56 % of total Revenue
Synthroid
   3.33 % of total Revenue
Other
   5.5 % of total Revenue
Synagis
   1.65 % of total Revenue
Sevoflurane
   2.16 % of total Revenue
Creon
   2.85 % of total Revenue
VIEKIRA
   8.32 % of total Revenue
Dyslipidemia products
   0.76 % of total Revenue
 

Business Segments (Sep. 30, 2015)
Revenues
(in millions $)
III. Quarter
%
(of total Revenues)
(Sep. 30, 2015)
Income
(in millions $)
III. Quarter
%
(Profit Margin)
HUMIRA
3,647.00 64.66 % 0.00 -
Kaletra
168.00 2.98 % 0.00 -
AndroGel
177.00 3.14 % 0.00 -
Lupron
201.00 3.56 % 0.00 -
Synthroid
188.00 3.33 % 0.00 -
Other
310.00 5.5 % 0.00 -
Synagis
93.00 1.65 % 0.00 -
Sevoflurane
122.00 2.16 % 0.00 -
Creon
161.00 2.85 % 0.00 -
VIEKIRA
469.00 8.32 % 0.00 -
Dyslipidemia products
43.00 0.76 % 0.00 -
Total
5,640.00 100 % 0.00 -

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (Sep. 30, 2015)
Y/Y Revenue
%
III. Quarter
Q/Q Revenue
%
(Sep. 30, 2015)
Y/Y Income
%
III. Quarter
Q/Q Income
%
HUMIRA
12.04 % 3.11 % - -
Kaletra
-34.38 % 0.6 % - -
AndroGel
-23.71 % 4.12 % - -
Lupron
2.55 % 1.52 % - -
Synthroid
-6 % 0.53 % - -
Other
-16.22 % 0.65 % - -
Synagis
-14.68 % 102.17 % - -
Sevoflurane
-8.96 % 3.39 % - -
Creon
8.78 % 1.26 % - -
VIEKIRA
- 21.82 % - -
Dyslipidemia products
-31.75 % 13.16 % - -
Total
12.37 % 5.07 % - -

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Abbvie Inc 's HUMIRA, Kaletra, AndroGel, Lupron, Synthroid, Other, Synagis, Sevoflurane, Creon, VIEKIRA, Dyslipidemia products, Total segment. Select each division with the arrow.

  Abbvie Inc 's

Business Segments Description



Pharmaceutical Products

The Pharmaceutical Products segment’s products include a broad line of adult and pediatric pharmaceuticals manufactured, marketed and sold worldwide, which are sold primarily on the prescription, or recommendation, of physicians. In 2006, Abbott announced a collaboration with AstraZeneca to co-develop and market a fixed-dose combination lipid management therapy of Crestor® (rosuvastatin/AstraZeneca) with either Tricor® (Abbott’s fenofibrate) or Abbott’s next generation fenofibrate, ABT 335.

The principal products included in the Pharmaceutical Products segment are:

· TriCor®, for the treatment of dyslipidemia;

· Niaspan®, for the treatment of high cholesterol;

· HUMIRA®, for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis;

· the anti-infectives clarithromycin (sold under the trademarks Biaxin®, Klacid® and Klaricid®), Omnicef®, an oral cephalosporin antibiotic, tosufloxacin, sold in Japan under the trademark Tosuxacin®, and various forms of the antibiotic erythromycin, sold primarily as PCE® or polymer-coated erythromycin, Erythrocin®, and E.E.S.®;

· Synthroid®, for the treatment of hypothyroidism;

· Meridia® and Reductil® (also marketed as Reductyl™ and Reductal™) for the treatment of obesity;

· the anti-virals Kaletra® and Norvir®, protease inhibitors for the treatment of HIV infection;

· Depakote®, an agent for the treatment of epilepsy and bipolar disorder and the prevention of migraines;

· the anesthesia products sevoflurane (sold in the United States under the trademark Ultane® and outside of the United States primarily under the trademark Sevorane® and in a few other markets as Ultane®), isoflurane, and enflurane;

· the specialty injectables Zemplar®, for the treatment of hyperparathyroidism, Calcijex®, and Survanta®;

· Lupron®, also marketed as Lucrin®, and Lupron Depot® used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids;

· Ogastro®, also marketed as Prevacid® (lansoprazole), a proton pump inhibitor for the short-term treatment of duodenal ulcers, gastric ulcers, and erosive esophagitis; and

· various cardiovascular products, including Mavik® (also marketed as Goptin®), Isoptin® and Tarka® for the treatment of hypertension.

   

Sales by Geography Competition By Business Segments Company Profile
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SNPY's Profile

Stock Price

SNPY's Financials

Business Description

Fundamentals

Charts & Quotes

SNPY's News

Suppliers

SNPY's Competitors

Customers & Markets

Economic Indicators

SNPY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071